Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
Identifieur interne : 000D78 ( PascalFrancis/Corpus ); précédent : 000D77; suivant : 000D79Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
Auteurs : Vincent Paille ; Philippe Brachet ; Philippe DamierSource :
- Neuroreport : (Oxford) [ 0959-4965 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 04-0446932 INIST |
---|---|
ET : | Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease |
AU : | PAILLE (Vincent); BRACHET (Philippe); DAMIER (Philippe) |
AF : | INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet/44093 Nantes/France (1 aut., 2 aut., 3 aut.); Clinique Neurologique and Centre d'Investigation Clinique, CHU/Nantes/France (3 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Neuroreport : (Oxford); ISSN 0959-4965; Royaume-Uni; Da. 2004; Vol. 15; No. 3; Pp. 561-564; Bibl. 21 ref. |
LA : | Anglais |
EA : | The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs. |
CC : | 002A25E; 002B17A01 |
FD : | Lésion; Modèle animal; Pathogénie; Lévodopa; Neurone dopaminergique; Mort cellulaire; Oxidopamine; Locus niger; Dyskinésie; Chronique; Mouvement involontaire; Parkinson maladie; Dopamine; Développement; Rat; Homme; Animal; Contrôle moteur |
FG : | Extrapyramidal syndrome; Système nerveux pathologie; Trouble neurologique; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien; Système nerveux central; Catécholamine; Neurotransmetteur; Rodentia; Mammalia; Vertebrata |
ED : | Lesion; Animal model; Pathogenesis; Levodopa; Dopaminergic neuron; Cell death; Oxidopamine; Locus niger; Dyskinesia; Chronic; Involuntary movement; Parkinson disease; Dopamine; Development; Rat; Human; Animal; Motor control |
EG : | Extrapyramidal syndrome; Nervous system diseases; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Antiparkinson agent; Central nervous system; Catecholamine; Neurotransmitter; Rodentia; Mammalia; Vertebrata |
SD : | Lesión; Modelo animal; Patogenia; Levodopa; Neurona dopaminérgica; Muerte celular; Oxidopamina; Locus níger; Disquinesia; Crónico; Movimiento involuntario; Parkinson enfermedad; Dopamina; Desarrollo; Rata; Hombre; Animal; Control motor |
LO : | INIST-22534.354000113564420350 |
ID : | 04-0446932 |
Links to Exploration step
Pascal:04-0446932Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0446932</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0446932 INIST</idno>
<idno type="RBID">Pascal:04-0446932</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D78</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animal model</term>
<term>Cell death</term>
<term>Chronic</term>
<term>Development</term>
<term>Dopamine</term>
<term>Dopaminergic neuron</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Involuntary movement</term>
<term>Lesion</term>
<term>Levodopa</term>
<term>Locus niger</term>
<term>Motor control</term>
<term>Oxidopamine</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Rat</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lésion</term>
<term>Modèle animal</term>
<term>Pathogénie</term>
<term>Lévodopa</term>
<term>Neurone dopaminergique</term>
<term>Mort cellulaire</term>
<term>Oxidopamine</term>
<term>Locus niger</term>
<term>Dyskinésie</term>
<term>Chronique</term>
<term>Mouvement involontaire</term>
<term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Développement</term>
<term>Rat</term>
<term>Homme</term>
<term>Animal</term>
<term>Contrôle moteur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-4965</s0>
</fA01>
<fA03 i2="1"><s0>Neuroreport : (Oxf.)</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PAILLE (Vincent)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BRACHET (Philippe)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DAMIER (Philippe)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>561-564</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22534</s2>
<s5>354000113564420350</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0446932</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroreport : (Oxford)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A25E</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lésion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lesion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Lesión</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Animal model</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathogénie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pathogenesis</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Patogenia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Mort cellulaire</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cell death</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Muerte celular</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Oxidopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Chronique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Chronic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Crónico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Développement</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Development</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Rata</s0>
<s5>54</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Homme</s0>
<s5>55</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Human</s0>
<s5>55</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hombre</s0>
<s5>55</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Contrôle moteur</s0>
<s5>70</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Motor control</s0>
<s5>70</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Control motor</s0>
<s5>70</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>27</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>28</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>29</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>250</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0446932 INIST</NO>
<ET>Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</ET>
<AU>PAILLE (Vincent); BRACHET (Philippe); DAMIER (Philippe)</AU>
<AF>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet/44093 Nantes/France (1 aut., 2 aut., 3 aut.); Clinique Neurologique and Centre d'Investigation Clinique, CHU/Nantes/France (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuroreport : (Oxford); ISSN 0959-4965; Royaume-Uni; Da. 2004; Vol. 15; No. 3; Pp. 561-564; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</EA>
<CC>002A25E; 002B17A01</CC>
<FD>Lésion; Modèle animal; Pathogénie; Lévodopa; Neurone dopaminergique; Mort cellulaire; Oxidopamine; Locus niger; Dyskinésie; Chronique; Mouvement involontaire; Parkinson maladie; Dopamine; Développement; Rat; Homme; Animal; Contrôle moteur</FD>
<FG>Extrapyramidal syndrome; Système nerveux pathologie; Trouble neurologique; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien; Système nerveux central; Catécholamine; Neurotransmetteur; Rodentia; Mammalia; Vertebrata</FG>
<ED>Lesion; Animal model; Pathogenesis; Levodopa; Dopaminergic neuron; Cell death; Oxidopamine; Locus niger; Dyskinesia; Chronic; Involuntary movement; Parkinson disease; Dopamine; Development; Rat; Human; Animal; Motor control</ED>
<EG>Extrapyramidal syndrome; Nervous system diseases; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Antiparkinson agent; Central nervous system; Catecholamine; Neurotransmitter; Rodentia; Mammalia; Vertebrata</EG>
<SD>Lesión; Modelo animal; Patogenia; Levodopa; Neurona dopaminérgica; Muerte celular; Oxidopamina; Locus níger; Disquinesia; Crónico; Movimiento involuntario; Parkinson enfermedad; Dopamina; Desarrollo; Rata; Hombre; Animal; Control motor</SD>
<LO>INIST-22534.354000113564420350</LO>
<ID>04-0446932</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:04-0446932 |texte= Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |